SURMOUNT-1 Trial: Tirzepatide Achieves Up to 22.5% Weight Loss in Adults Without Diabetes
Medically reviewed by Dr. James Whitfield, DO, FACOI
The SURMOUNT-1 trial, published in the New England Journal of Medicine in 2022 by Jastreboff et al., was the landmark study that established tirzepatide as the most effective anti-obesity medication ever tested. With 2,539 participants, the 15mg dose achieved a mean 22.5% body weight reduction over 72 weeks — results that rivaled bariatric surgery.
The SURMOUNT-1 Trial: Redefining What's Possible in Obesity Medicine
The SURMOUNT-1 trial represents a watershed moment in the treatment of obesity. Published in the New England Journal of Medicine in July 2022 by Jastreboff et al., this double-blind, randomized, placebo-controlled Phase 3 trial demonstrated that once-weekly tirzepatide — a first-in-class dual GIP and GLP-1 receptor agonist — produced weight loss of a magnitude never before seen with any pharmaceutical agent [1].
Study Design and Population
SURMOUNT-1 enrolled 2,539 adults across 119 sites in 9 countries. Eligibility required a body mass index (BMI) of 30 or greater, or a BMI of 27 or greater with at least one weight-related comorbidity (hypertension, dyslipidemia, or obstructive sleep apnea). Crucially, participants did not have type 2 diabetes, isolating the weight loss effects from glucose-lowering confounders.
Participants were randomized 1:1:1:1 to receive tirzepatide 5 mg, 10 mg, or 15 mg, or placebo via once-weekly subcutaneous injection for 72 weeks. All groups received lifestyle intervention counseling (500 kcal/day deficit and ≥150 minutes/week of physical activity).
The dose escalation schedule was designed to improve tolerability: all tirzepatide groups started at 2.5 mg weekly and escalated by 2.5 mg every 4 weeks until reaching their assigned dose.
---
> Need help building the right stack? The clinical team at Telegenix designs personalized peptide and hormone protocols based on your labs, goals, and medical history. Schedule a free consultation.
---
Primary Efficacy Results
The results were unprecedented across all three tirzepatide doses:
Mean Body Weight Change at 72 Weeks:
Categorical Weight Loss Thresholds (15 mg dose):
The 22.5% mean weight loss with the 15 mg dose was approximately 50% greater than the 14.9% achieved by semaglutide 2.4 mg in the STEP 1 trial, establishing tirzepatide as the new benchmark in pharmacological weight management [1].
The Dual Agonist Mechanism
Tirzepatide's superior weight loss is attributed to its unique dual mechanism:
GLP-1 Receptor Agonism:
GIP Receptor Agonism:
This dual action creates a synergistic effect that exceeds what either pathway achieves alone, explaining why tirzepatide produces greater weight loss than pure GLP-1 receptor agonists like semaglutide [2].
Cardiometabolic Improvements
Beyond weight loss, SURMOUNT-1 demonstrated comprehensive cardiometabolic benefits:
These improvements suggest that tirzepatide addresses the metabolic syndrome broadly, not just body weight [1].
Safety Profile
The safety data from SURMOUNT-1 were consistent with the GLP-1 receptor agonist class:
Gastrointestinal Adverse Events (15 mg):
Most GI events were mild to moderate and occurred during the dose-escalation phase. Importantly, the gradual 4-week dose escalation helped mitigate the severity of these side effects.
Discontinuation rates due to adverse events were 4.3% (5 mg), 7.1% (10 mg), and 6.2% (15 mg) vs. 2.6% (placebo).
Serious adverse events occurred at similar rates across groups (5-7%), with no new safety signals identified. Gallbladder events were slightly more common with tirzepatide, consistent with rapid weight loss [1].
Comparison to Bariatric Surgery
The 22.5% weight loss with tirzepatide 15 mg approaches the range typically achieved with certain bariatric procedures:
| Intervention | Typical Weight Loss | Invasiveness |
|---|---|---|
| Gastric banding | 15-20% | Surgical |
| Sleeve gastrectomy | 25-30% | Surgical |
| Roux-en-Y gastric bypass | 30-35% | Surgical |
| Tirzepatide 15 mg | 22.5% | Weekly injection |
While bariatric surgery still produces greater average weight loss, tirzepatide offers a non-surgical alternative that achieves results in the same range as less invasive surgical procedures [1].
Impact on Obesity Treatment
SURMOUNT-1 fundamentally changed the obesity treatment landscape:
> Related Comparison: Ozempic vs Mounjaro: Complete Comparison
References
---
> Ready to put this research into practice? Telegenix provides evidence-based peptide and TRT protocols supervised by licensed providers. Get a personalized plan built around your bloodwork. Start with a free consultation.
---
Related Reading
Explore more in-depth guides on related topics:
For a comprehensive overview, see our Complete Guide to Peptide Therapy.
---